Altimmune Posts Q4 FY25 Earnings Miss, Revenue Above Expectations

Altimmune reported a FY25 GAAP EPS of -$0.27, missing analyst expectations by $0.03. The company posted some revenue despite the earnings miss. Big Pharma is staying away from the company, which has struggled to gain traction with its vaccine candidates. The company's financials show a mixed picture, with some revenue generated but overall poor performance.